Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis

The Lancet

Volumn 384, Issue 9961, 2014, Pages 2228-2234

  Eng, Conrad ^a   Kramer, Caroline K ^a,c   Zinman, Bernard ^a,b,c   Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

AGONISTS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84919344081     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61335-0     Document Type: Article

References (31)

1. SE Kahn, S Zraika, KM Utzschneider, RL Hull The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality Diabetologia 52 2009 1003 1012
2. CJ Nolan, P Damm, M Prentki Type 2 diabetes across generations: from pathophysiology to prevention and management Lancet 378 2011 169 181
3. BL Wajchenberg Beta-cell failure in diabetes and preservation by clinical treatment Endocr Rev 28 2007 187 218
4. SE Inzucchi, RM Bergenstal, JB Buse et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
5. T Vilsboll, M Christensen, AE Junker, FK Knop, LL Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
6. DJ Drucker, MA Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
7. JE Campbell, DJ Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 2013 819 837
8. R Balena, IE Hensley, S Miller, AH Barnett Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature Diabetes Obes Metab 15 2013 485 502
9. JJ Holst, T Vilsboll Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings Diabetes Obes Metab 15 2013 3 14
10. D Moher, A Liberati, J Tetzlaff, DG Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
11. AJ RH Ahmann, J Rosenstock, J Lahtela et al. Efficay and saftey of liraglutide vs. placebo when added to basal insulin analogs in patients with type 2 diabetes (LIRA-ADD2BASAL) Diabetes 63 suppl 1 2014 A87
12. S Duval, R Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
13. JP Higgins, SG Thompson, JJ Deeks, DG Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
14. JP Higgins, SG Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
15. JB Buse, RM Bergenstal, LC Glass et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 154 2011 103 112
16. JH DeVries, SC Bain, HW Rodbard et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets Diabetes Care 35 2012 1446 1454
17. CJ Li, J Li, QM Zhang et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity Cardiovasc Diabetol 11 2012 142
18. Y Seino, KW Min, E Niemoeller, A Takami Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes Obes Metab 14 2012 910 917
19. MC Riddle, T Forst, R Aronson et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 36 2013 2497 2503
20. MC Riddle, R Aronson, P Home et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 36 2013 2489 2496
21. M Diamant, MA Nauck, R Shaginian et al. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in diabetes Diabetes Care 2014 10.2337/dc14-0876 published online July 10.
22. W Lane, S Weinrib, J Rappaport, C Hale The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial Diabetes Obes Metab 2014 10.1111/dom.12286 published online March 3.
23. C Mathieu, HW Rodbard, B Cariou et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON) Diabetes Obes Metab 16 2014 636 644
24. J Rosenstock, VA Fonseca, JL Gross et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro Diabetes Care 2014 10.1111/dom.12286 published June 4.
25. N Shao, HY Kuang, M Hao, XY Gao, WJ Lin, W Zou Effects of exenatide on obesity and NAFLD with elevated liver enzymes in patients with type 2 diabetes Diabetes Metab Res Rev 2014 10.1002/dmrr.2561 published online May 13.
26. HM de Wit, GM Vervoort, HJ Jansen, WJ de Grauw, BE de Galan, CJ Tack Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT) Diabetologia 2014 10.1007/s00125-014-3302-0 published online June 20.
27. J DM Rosenstock, L Silvestre, E Souhami, T Zhou, V Fonesca Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixenatide (LixiLan) vs glargine in type 2 diabetes (T2DM) inadequately controlled on metformin Diabetes 63 suppl 1 2014 A87 A88
28. Y KS Seino, S Fukuda, T Osonoi, T Shiraiwa, K Nishijima, K Kaku Combination therapy with liraglutide and insulin in Japanese subjects with type 2 diabetes: the LIRA-ADD2INSULIN JAPAN trial Diabetes 63 suppl 1 2014 A253
29. SE Kahn, SM Haffner, MA Heise et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
30. JJ Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat Rev Endocrinol 8 2012 728 742
31. JB Buse, J Rosenstock, G Sesti et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47